Phase 2 Safety Trial of AT-1501 Nears Full Enrollment of Patients

Phase 2 Safety Trial of AT-1501 Nears Full Enrollment of Patients

310167

Phase 2 Safety Trial of AT-1501 Nears Full Enrollment of Patients

A Phase 2 study of the investigational antibody AT-1501 in treating amyotrophic lateral sclerosis (ALS) has completed patient enrollment in three of its four dosing groups, and is likely to be fully enrolled by year’s end, its developer, Eledon Pharmaceuticals, announced. A total of 54 ALS patients diagnosed in the previous two years are expected to participate in this safety and tolerability trial (NCT04322149). Recruitment is ongoing at 12 sites in the U.S. and one in Canada…

You must be logged in to read/download the full post.